Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
165.81
+2.82 (1.73%)
At close: Jun 22, 2026, 4:00 PM EDT
165.68
-0.13 (-0.08%)
After-hours: Jun 22, 2026, 7:54 PM EDT
Revolution Medicines Employees
Revolution Medicines had 883 employees as of December 31, 2025. The number of employees increased by 349 or 65.36% compared to the previous year.
Employees
883
Change (1Y)
349
Growth (1Y)
65.36%
Revenue / Employee
n/a
Profits / Employee
-$1,553,455
Market Cap
35.25B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 883 | 349 | 65.36% |
| Dec 31, 2024 | 534 | 156 | 41.27% |
| Dec 31, 2023 | 378 | 132 | 53.66% |
| Dec 31, 2022 | 246 | 58 | 30.85% |
| Dec 31, 2021 | 188 | 63 | 50.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,088 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
RVMD News
- 19 hours ago - Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. - GlobeNewsWire
- 14 days ago - RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position - TheFly
- 14 days ago - Tango Therapeutics announces data from study of vopimetostat, daraxonrasib - TheFly
- 20 days ago - Revolution Medicines price target raised to $182 from $165 at RBC Capital - TheFly
- 21 days ago - Wedbush reiterates Outperform on Revolution Medicines after ASCO data - TheFly
- 21 days ago - Revolution Medicines price target raised to $195 from $169 at H.C. Wainwright - TheFly
- 21 days ago - Revolution Medicines price target raised to $195 from $165 at Oppenheimer - TheFly
- 21 days ago - Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - Reuters